NEW YORK, Dec. 10 - UBS Warburg on Monday began research coverage of Luminex with a "buy" rating and a $21 price target, according to the financial firm.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times reports that as China invests in science, it also is dealing with research fraud.
In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.
The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.
Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.